ThinkstockAgilent Technologies Inc. (NYSE: A) reported third fiscal quarter 2015 earnings after markets closed Monday. For the quarter, healthcare company posted adjusted diluted earnings per share (EPS) of $0.44 on revenues of $1.01 billion.…
ThinkstockAMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) had already seen shares rise handily prior to the summer selloff. While this deal is a known event, it looks as though AMAG may have just scored after it…
Thinkstock Medical device maker SynCardia Systems, Inc. filed an S-1 form with the Securities and Exchange Commission (SEC) for its initial public offering (IPO). There were no terms given in the filing but the offering…
Kite Pharma gave an update from its ongoing Phase 1/2 clinical trial of KTE-C19 in patients with refractory aggressive non-Hodgkin's lymphoma.
Aveo Pharmaceuticals made waves in early trading indications Monday on news of a licensing agreement with Novartis.
Credit Suisse assumed coverage with handy upside in the CRO leaders, and on average the firm is calling for upside of about 15%.
Onconova Therapeutics has announced the submission of an investigational new drug application to the FDA.
Aquinox Pharmaceuticals has made an absolutely ridiculous run in the past week alone, proving that it is a day trader’s dream.
In a new research report, JPMorgan highlights its favorite biotech stocks to buy after the second-quarter earnings print.
Bristol-Myers Squibb announced that the FDA has now extended the action date for the supplemental biologics license application for Opdivo in the war against advanced melanoma.
A biopharmaceutical company working on developing and commercializing treatments for serious blood-based disorders priced its initial public offering (IPO) above the expected range Tuesday.
Eleven Biotherapeutics was at the top of the list for gainers in the market Wednesday. This move comes on an update from the company’s most advanced study.
The short interest data have been released for the July 31 settlement date, and for most of the selected pharmaceutical stocks, short interest decreased.
The short interest data are out for the July 31 settlement date, and overall, short interest in the selected biotech stocks backed off for this period.
It may be impossible to ever know if a true bottom has ever been seen, but many investors love finding great companies where they feel that a sell-off has overly punished the share price.